Feil Family Brain & Mind Research Institute

You are here

Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity.

TitleEpigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity.
Publication TypeJournal Article
Year of Publication2019
AuthorsGoldman SL, Hassan C, Khunte M, Soldatenko A, Jong Y, Afshinnekoo E, Mason CE
JournalFront Genet
Volume10
Pagination133
Date Published2019
ISSN1664-8021
Abstract

Leukemia, specifically acute myeloid leukemia (AML), is a common malignancy that can be differentiated into multiple subtypes based on leukemogenic history and etiology. Although genetic aberrations, particularly cytogenetic abnormalities and mutations in known oncogenes, play an integral role in AML development, epigenetic processes have been shown as a significant and sometimes independent dynamic in AML pathophysiology. Here, we summarize how tumors evolve and describe AML through an epigenetic lens, including discussions on recent discoveries that include prognostics from epialleles, changes in RNA function for hematopoietic stem cells and the epitranscriptome, and novel epigenetic treatment options. We further describe the limitations of treatment in the context of the high degree of heterogeneity that characterizes acute myeloid leukemia.

DOI10.3389/fgene.2019.00133
Alternate JournalFront Genet
PubMed ID30881380
PubMed Central IDPMC6405641
Grant ListR01 MH117406 / MH / NIMH NIH HHS / United States
R01 AI125416 / AI / NIAID NIH HHS / United States
R01 ES021006 / ES / NIEHS NIH HHS / United States
R25 EB020393 / EB / NIBIB NIH HHS / United States
R21 AI129851 / AI / NIAID NIH HHS / United States
R01 NS076465 / NS / NINDS NIH HHS / United States